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Abstract
Background: Low expression thymidylate synthase (TS) polymorphism has been associated with increased stavudine
triphosphate intracellular (d4T-TP) levels and the lipodystrophy syndrome. The use of d4T has been associated with acute
pancreatitis and peripheral neuropathy. However, no relationship has ever been proved between TS polymorphisms and
pancreatitis and/or peripheral neuropathy.
Methods: We performed a case-control study to assess the relationship of TS and methylene-tetrahydrofolate reductase
(MTHFR) gene polymorphisms with acute pancreatitis and/or peripheral neuropathy in patients exposed to d4T. Student’s t
test, Pearson’s correlations, one-way ANOVA with Bonferroni correction and stepwise logistic regression analyses were
done.
Results: Forty-three cases and 129 controls were studied. Eight patients (18.6%) had acute pancreatitis, and 35 (81.4%) had
peripheral neuropathy. Prior AIDS was more frequent in cases than in controls (OR= 2.36; 95%CI 1.10–5.07, P = 0.0247). L7ow
expression TS and MTHFR genotype associated with increased activity were more frequent in patients with acute
pancreatitis and/or peripheral neuropathy than in controls (72.1% vs. 46.5%, OR= 2.97; 95%CI: 1.33–6.90, P = 0.0062, and
79.1% vs. 56.6%, OR= 2.90, 95%CI: 1.23–7.41, P = 0.0142, respectively). Independent positive or negative predictors for the
development of d4T-associated pancreatitis and/or peripheral neuropathy were: combined TS and MTHFR genotypes
(reference: A+A; P = 0.002; ORA+B = 0.34 [95%CI: 0.08 to 1.44], ORB+A = 3.38 [95%CI: 1.33 to 8.57], ORB+B = 1.13 [95%CI: 0.34 to
3.71]), nadir CD4 cell count .200 cells/mm3 (OR= 0.38; 95%CI: 0.17–0.86, P = 0.021), and HALS (OR= 0.39 95%CI: 0.18–0.85,
P = 0.018).
Conclusions: Low expression TS plus a MTHFR genotype associated with increased activity is associated with the
development of peripheral neuropathy in d4T-exposed patients.
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Introduction
The doubtless efficacy of highly active antiretroviral therapy
(HAART) is still shadowed by drug toxicity, specially that
appearing in the long-term [1]. Some of the most important toxic
effects experienced by patients on HAART are caused by the
nucleoside reverse transcriptase inhibitor (NRTI) part of the
regime [2]. Among NRTI-associated toxicity, that caused by
thymidine analogues, namely zidovudine (AZT) and stavudine
(d4T) stands out. The common mechanism underlying thymidine
analogues’ toxic effects is mitochondrial toxicity [3]. The ability of
the triphosphate active NRTI to inhibit mitochondrial gamma
polymerase causes mitochondrial DNA depletion that may
eventually lead to mitochondrial respiratory chain protein de-
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pletion which in turn leads to mitochondrial dysfunction [4]. This
can ultimately cause cellular dysfunction or even cellular death [5].
The ability of thymidine analogues to inhibit mitochondrial
gamma polymerase will depend on the intracellular concentrations
of their triphosphate metabolites [6]. Therefore, all the circum-
stances increasing the levels of these metabolites may be
accompanied by a higher degree of mitochondrial toxicity [7].
We recently described how thymidylate synthase (TS) polymorph-
isms may modify d4T triphosphate (d4T-TP) intracellular
concentrations, and how higher intracellular levels of d4T-TP
are associated with the HIV/HAART-associated lypodystrophy
syndrome (HALS) [7,8].
Our working hypothesis was that TS and MTHFR polymorph-
isms could be associated with other manifestations of mitochon-
drial toxicity, such as d4T-associated pancreatitis and d4T-
associated peripheral neuropathy. To test this hypothesis we
performed a case-control study in d4T-exposed patients who
developed pancreatitis or peripheral neuropathy while on d4T-
based therapy.
Patients and Methods
Population Studied
All patients and controls were recruited at the same HIV-1
infection clinic at the Hospital de la Santa Creu i Sant Pau, which
attended a population of 3355 HIV-1-infected patients between
1994 and 2010. All were patients on active follow up with an
established diagnosis of HIV-1 infection on d4T-based antire-
troviral therapy. Patients were eligible if they had developed
pancreatitis and/or peripheral neuropathy while receiving therapy
with d4T as part of their antiretroviral regimes. Controls were
subjects followed in the same cohort who did not develop
pancreatitis and/or neuropathy while on d4T therapy. Controls
were selected in a 3:1 ratio with respect to cases. They were
matched to patients with respect to age (65 years), sex, and
exposure to d4T (but not time on d4T). A normal dose of d4T was
40 mg twice daily if the patient weighed .60 kg, and 30 mg twice
daily if the patient weighed ,60 kg, whereas a reduced dose was
30 mg/12 h and 20 mg/12 h for patients with a weight of $60 or
,60 kg, respectively. Subjects who were hospitalized or had
a frank cognitive impairment such as delirium or dementia on
enrolment were not eligible. Patients with opportunistic infections,
neoplasms or fever of undetermined origin were excluded from the
study too. Written informed consent was obtained from the
patients at study entry. The study was approved by the Ethics
Committee of the Hospital de la Santa Creu i Sant Pau.
Definition of Clinical Endpoints
A case of acute pancreatitis was defined as a clinical history
consistent with pancreatitis (i.e. abdominal pain with or without
findings of shock and hypotension where other causes of
abdominal pain have been excluded) with supporting biochemical
evidence of pancreatitis: elevated lipase (3 times the upper normal
limit) or amylase (3 times the upper normal limit) and evidence of
pancreatitis from radiological investigation or hemorrhagic
pancreatitis at laparotomy or post-mortem exam [9,10]. Asymp-
tomatic elevations of pancreatic enzymes were not considered to
be cases of acute pancreatitis. Chronic pancreatitis cases were
excluded from the study.
The diagnosis of neuropathy (sensory or mixed) required the
presence of numbness, paresthesias, or dysesthesias in the patient’s
lower or lower and upper extremities with onset after starting
a d4T-based antiretroviral regime [11,12]. A confirmatory
electromyogram or a nerve conduction analysis was not a com-
pulsory criterion for the diagnosis of neuropathy. The diagnosis of
AIDS was based on the 1993 revised case definition of the Centers
for Disease Control and Prevention [13].
The presence or absence of lipoatrophy, lipohypertrophy, and
mixed syndrome was determined as previously described [7]. The
metabolic syndrome was defined according to the U.S. National
Cholesterol Education Program (NCEP) Adult Treatment Panel
III Guidelines [14] and modified as recommended in the latest
American Heart Association/National Heart, Lung, and Blood
Institute Scientific Statement [15]. Alcohol abuse was defined
when alcohol intake was .40 g daily [16].
Biochemistry Laboratory Measurements
All laboratory investigations were performed after a 12 h
overnight fast and at least 15 minutes after the placement of
a peripheral intravenous catheter, as previously described [7,8].
Genotyping Analyses
The genomic DNA was extracted from the peripheral
leucocytes by the salting-out procedure [17]. In the TS gene, the
variable number tandem repeat (VNTR) of 28 bp polymorphism
and the GRC SNP in the first and second repeat were analyzed. A
DNA fragment was amplified using previously described PCR
conditions and primers [7,8], and directly sequenced using an ABI
PRISM 3100 Genetic Analyzer (Applied Biosystems, Foster City,
CA, USA). This G to C substitution changes a critical residue in
the USF E-box consensus element, abolishes USF-1 binding, and
alters transcriptional activity. TS genotypes of the patients were
classified according to Kawakami and Watanabe into two groups:
high expression type (2/3G, 3C/3G and 3G/3G) and low
expression type (2/2, 2/3C and 3C/3C) [18].
The MTHFR gene polymorphisms (677CRT [rs1801133] and
1298 ARC [rs1801131) were determined. These two polymorph-
isms were analyzed using Fluidigm’s Biomark system. This
technology is designed for the allelic discrimination 59 nuclease
assay. The samples and the TaqMan Gene expression assays
(Applied Biosystems, Foster City, CA, USA) were prepared
following manufacturer’s instructions. The 48.48 dynamic arrays
used were automatically loaded using an IFC Controller (Fluidigm
Corporation), and real-time reactions were performed and
analyzed using BioMark Real-Time PCR System and Analysis
software (Fluidigm Corporation), respectively. As a quality control,
normal, heterozygote and homozygote sequenced samples were
included on every array for each genotype. MTHFR genotypes
were classified also into two groups: those associated with
a decreased enzymatic activity (homozygous 677T, homozygous
1298C and compound heterozygous patients), and genotypes
associated with an increased enzymatic acitivity (heterozygous and
wild-type patients) [19]. Combined TS and MTHFR genotypes
with respect to enzyme activities produced four groups: low TS
expression and increased MTHFR activity (B+A), ow TS
expression and decreased MTHFR activity (B+B), high TS
expression and increased MTHFR activity (A+A), and high TS
expression and decreased MTHFR activity (A+B).
Statistical Analyses
Data are expressed as median with interquartile range (IQR) or
as otherwise specified. Continuous variables were assessed with the
nonparametric Mann-Whitney test and categorical data such as
genotype and allele frequencies were compared by use of the
Fisher’s exact test. The level of significance was established at the
0.05 level and all reported P values are two-sided. A logistic
regression analysis was used to examine the association of
peripheral neuropathy and/or pancreatitis with TS and MTHFR
TS/MTHFR Genotypes in Peripheral Neuropathy in HIV
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polymorphisms and other parameters; variables associated with
a P,0.1 in the univariate analyses were included in the
multivariate stepwise analysis. All analyses were performed with
the SAS version 9.1.3 software (SAS Institute Inc., Cary, NC).
Results
Population Studied
From January 1994 to December 2010, there were 102 cases of
pancreatitis and/or peripheral neuropathy in our cohort; 34 cases
of pancreatitis, 62 peripheral neuropathies and 6 cases with both
pancreatitis and neuropathy. Of them, 63 (61.7%) were associated
with d4T exposure, which had been taken at any time by 899
patients for a total exposure of 39,684 months. The incidence of
d4T-associated pancreatitis and/or neuropathy was 19.05 (95%
CI: 14.28–24.39) cases per 1000 patient-years (PY) in those
exposed to d4T and 4.28 (3.13–5.86) in those not exposed
(P,0.0001). For peripheral neuropathy the incidences were 18.75
(14.62–24.05) and 1.98 (1.25–3.14), respectively (P,0.0001),
whereas for pancreatitis they were 10.28 (7.35–14.39) and 2.3
(1.50–3.54), respectively (P,0.0001). We studied 172 HIV-1-
infected, Caucasian patients, exposed to a d4T-based therapy (43
cases and 129 controls). There were no differences between the 43
cases studied and the 20 patients excluded because of lack of DNA.
Demographic, means of acquiring HIV-1 infection and the
immunovirological status of patients and controls are shown in
table 1. There were 127 men (73.8%) and 45 women (26.2%), with
a mean age of 51.1610.9 years (median: 49.0 [IQR: 42.0–58.0]
years). Sixty-nine patients (40.1%) had had a prior AIDS-defining
condition. Eight patients (18.6%) had pancreatitis, and 35 (81.4%)
had peripheral neuropathy. Prior AIDS was significantly more
frequent in cases than in controls (OR=2.36; 95%CI: 1.10–5.07,
P = 0.0247). No patient was diabetic or was using insulin or
hypoglycemic agents. Alcohol abuse was documented in 11
patients (6.3%). The median daily alcohol consumption for
alcohol abusers was 63.0 (IQR: 55.0–94.5) grams, without
statistically significant differences between cases and controls
(P = 0.8738).
Antiretroviral Drug Exposure and Immunovirological
Status
Most of the patients (124, 72.9%) had undetectable viral load at
the time of the study. The median viral load for those who had it
detectable was 2.0 (IQR: 1.68–3.06) log10 copies/ml. The mean
CD4 count was 5896291 cells/mm3 (median: 539 [IQR: 383–
784]). Nadir CD4 cell count was ,200 cells/mm3 in 109 patients
(60.5%) and ,100 cells/mm3 in 75 (41.7%). A CD4 cell count
nadir ,200 cells/mm3 was significantly more frequent in cases
(OR=2.34; 95%CI: 1.03–5.58, P= 0.0437) (Table 1). The
maximum viral load was above 5 log10 copies/ml in 106 patients
(61.6%). Four cases (9.3%) and 31 controls (24.0%) were receiving
reduced d4T doses (OR=0.32; 95%CI: 0.08–1.01, P = 0.0630).
The cumulated exposure to antiretroviral drugs is shown in table 2.
More cases than controls were receiving d4T plus ddI at event
(53.5% vs. 34.1%, OR=2.22; 95%CI: 1.04–4.76, P = 0.0379).
None of the patients was receiving hydroxyurea.
Metabolic Data, Metabolic Syndrome and HALS
Metabolic and fat data are shown in table 3. There were no
differences between cases and controls with respect to anthropo-
metric and metabolic parameters. Sixty-nine patients (38.3%) had
metabolic syndrome, without differences between cases and
controls (OR=1.59; 0.75–3.32, P= 0.2498). Ninety-three patients
(54.1%) had HALS. HALS was less frequent in cases than in
controls (41.9% vs. 58.1%, OR=0.52; 95%CI: 0.24–1.10,
P= 0.0932).
TS and MTHFR Polymorphisms, and Development of
Pancreatitis and/or Peripheral Neuropathy
The distribution of the different genotypes is shown in table 4.
Ninety-one patients (52.9%) had a low expression TS genotype.
This genotype was more frequent in patients with pancreatitis
and/or peripheral neuropathy than in controls (72.1% vs. 46.5%,
OR=2.97; 95%CI: 1.33–6.90, P= 0.0062). The association
remained statistically significant when peripheral neuropathy
alone was considered (68.6% vs. 46.5%, OR=2.51; 95%CI:
1.07–6.14, P= 0.0336), whereas there was a trend to significance
for pancreatitis (87.5% vs. 46.5%, OR=8.05; 95%CI: 0.98–
367.94, P= 0.0592). Neither 677CRT (P= 0.1119) or 1298ARC
(P= 0.0708) MTHFR polymorphisms were associated with the
development of pancreatitis and/or peripheral neuropathy.
However, when functional translation was taken into account
MTHFR genotypes associated with increased enzymatic activity
were more frequent in cases than in controls (79.1% vs. 56.6%,
OR=2.90, 95%CI: 1.23–7.41, P = 0.01423). The association
remained statistically significant for peripheral neuropathy
(77.1% vs. 58.4%, OR=2.40, 95%CI: 0.97–6.55, P = 0.0417),
but not for pancreatitis (87.5% vs. 60.9%, OR=4.48, 95%CI:
0.55–205.51, P= 0.2553).
Combined TS and MTHFR genotypes with respect to
peripheral neuropathy or pancreatitis are shown in table 4, where
it is apparent that those combinations with a greater negative
impact on TS activity were more frequently seen in cases.
Factors Associated with Development of Pancreatitis
and/or Peripheral Neuropathy
A multivariable analysis was performed taking as the dependent
variable the development of pancreatitis and/or peripheral
neuropathy and as independent variables, age, sex, AIDS, CD4
count nadir ,200/mm3, CD4 nadir ,100/mm3, d4T exposure
(m), d4T exposure (g), d4T exposure (mg/kg), AZT exposure (m),
AZT exposure (g), ABC exposure (m), d4T plus ddI at event, EFV
exposure (m), PI exposure (m), NRTI exposure (m), HALS, TS
genotype (low vs. high expression),MTHFR genotype (increased
vs. decreased enzymatic activity), and combined TS and MTHFR
genotypes, all variables associated with a P value ,0.1 in the
univariate analysis. Independent positive or negative predictors for
the development of d4T-associated pancreatitis and/or peripheral
neuropathy were: combined TS and MTHFR genotypes (refer-
ence: A+A; P= 0.002; ORA+B= 0.34 [95%CI: 0.08 to 1.44],
ORB+A= 3.38 [95%CI: 1.33 to 8.57], ORB+B= 1.13 [95%CI:
0.34 to 3.71]), nadir CD4 cell count .200 cells/mm3 (OR=0.38;
95%CI: 0.17–0.86, P= 0.021), and HALS (OR=0.39 95%CI:
0.18–0.85, P= 0.018).
Discussion
Our study suggests an association between TS and MTHFR
polymorphisms and the appearance of d4T-related toxicity in the
form of acute pancreatitis or peripheral neuropathy. However, our
work has inherent limitations. First, this is a case-control study and
therefore no causal relationships should or must be drawn.
Second, in case-control studies endpoint verification is of
paramount importance. It is known that peripheral neuropathy
or acute pancreatitis in the setting of HIV-1 infection treated with
HAART may be caused not only by antiretroviral drugs but also
by other drugs, alcohol abuse, or biliary stones and hypertrigly-
ceridemia in the case of pancreatitis [20]. On the other hand,
TS/MTHFR Genotypes in Peripheral Neuropathy in HIV
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there is no pathognomic test to etiologically ascribe the etiology of
peripheral neuropathy or pancreatitis. Notwithstanding that, none
of these well-known causes was present when patients in the study
were diagnosed as having peripheral neuropathy or pancreatitis,
except for alcohol abuse which in fact was more frequent among
controls. Unfortunately, when the study was performed, in-
tracellular d4T-TP concentrations in PBMCs were not available.
Third, d4T is a well-known cause of peripheral neuropathy and
pancreatitis, especially when combined with didanosine (ddI) or
even more when combined with ddI and hydroxyurea [21].
Among our cases, 23 (53.5%) were also exposed to ddI, which may
have contributed to the development of pancreatitis and/or
peripheral neuropathy. Although cumulated exposure to ddI was
not different in cases and controls, taking d4T plus ddI at event
was statistically more frequent in cases. However, taking both
drugs in combination was not an independent predictor for the
development of peripheral neuropathy and/or acute pancreatitis.
Fourth, there are a number of gene markers which have been
associated with the risk of developing both toxic peripheral
neuropathy and pancreatitis in HIV-infected patients on HAART,
such as cystic fibrosis trans-membrane conductance regulator
(CTR) and serine protease inhibitor kazal-1 (SPINK-1) mutations
for pancreatitis and mitochondrial haplotype T for peripheral
neuropathy [22–24]. We cannot exclude the possibility that some
of these untested genes may have contributed to acute pancreatitis
and/or peripheral neuropathy in our patients.
Acute pancreatitis in the setting of HIV infection and
antiretroviral therapy has wide incidence rates ranging from
1.27 to 22.6events/1000 PY [25–28]. These wide incidence rates
may be explained by different diagnostic criteria (clinical vs.
laboratory-based), and by the fact that some of the studies were
performed in early calendar years, when more toxic drugs were
used. Its appearance has been linked to the classical risk factors;
i.e. alcohol abuse, hypertriglyceridemia, as well as to the use of
antiretroviral drugs such as d4T and ddI [25–27]. The incidence
rates for peripheral neuropathy have also been very wide, ranging
from 0.7 to 39.7/1000 PY [29]. Known risk factors for developing
peripheral neuropathy in HAART-treated patients include alcohol
abuse, treatment with other neuropathic drugs (isoniazid, meth-
otrexate,…), factors which were ruled out in our patients [30].
However, sometimes it is difficult to distinguish toxic peripheral
neuropathy from exacerbation of HIV-associated neuropathy in
HAART-treated patients, which may also contribute to these
varying incidence rates. Notwithstanding that, none of our patients
had clinical features consistent with peripheral neuropathy prior to
taking d4T. The incidence of both acute pancreatitis and
peripheral neuropathy in our work fall within these wide ranges,
most probably because our study period spans throughout a long
Table 1. Demographics and immunovirological status of the population studied.
Cases (N=43) Controls (N=129) P value
Age (yrs.) 48.0 (43.0–57.7) 50.0 (42.0–58.2) 0.9042
Males, n (%) 32 (74.4) 95 (73.6) 0.9999
Risk group
MsM, n (%) 17 (39.5) 45 (34.9) 0.3366
Htsx, n (%) 14 (32.5) 55 (42.6)
IDU, n (%) 11 (23.2) 30 (21.7)
Other*, n (%) 2 (4.6) 1 0.8)
Years since diagnosis 13.0 (9.0–15.7) 13.0 (10.0–17.0) 0.4065
AIDS, n (%) 24 (55.8) 45 (34.9) 0.0195
Smokers, n (%) 17 (39.5) 70 (54.3) 0.1138
Alcohol abuse, n (%) 1 (2.3) 10 (7.7) 0.2952
HBV co-infection, n (%) 6 (13.9) 11 (8.5) 0.3751
HCV co-infection, n (%) 13 (30.2) 40 (31.0) 0.9999
Current CD4 count, cells/mm3 515 (346–730) 543 (388–792) 0.5430
CD4 increase, cells/mm3 386 (194–574) 339 (207–553) 0.6044
Current CD8 count cells/mm3 834 (582–1181) 874 (617–1146) 0.6521
CD8 increase, cells/mm3 555 (144–799) 370 (122–594) 0.1180
Nadir CD4 cell count, cells/mm3 83 (23–206) 182 (54–314) 0.0091
Nadir CD4 cell count ,100 cells/mm3, n (%) 24 (55.8) 45 (35.1) 0.0201
Nadir CD4 cell count ,200 cells/mm3, n (%) 32 (74.4) 71 (55.5) 0.0314
Viral load, log10, copies/ml 1.28 (1.28–1.28) 1.28 (1.28–1.55) 0.8307
Undetectable viral load, n (%) 33 (76.7) 91 (70.5) 0.5564
Maximum viral load, log10, copies/ml 5.46 (4.70–5.79) 5.19 (4.29–5.58) 0.1479
Maximum viral load $5 log10, copies/ml 31 (68.9) 75 (55.6) 0.0643
Viral load decrease, log10, copies/ml 3.78 (2.84–4.28) 3.58 (2.53–4.16) 0.3725
Values are expressed as median and interquartile range, unless indicated.
*includes 2 patients with post-transfusion HIV and 1 with unknown risk, MsM=men who have sex with men, HTSX =heterosexuals, IDU = intravenous drug users,
AIDS = acquired immune deficiency syndrome, HCV= hepatitis C virus, HBV =hepatitis B virus, ml =milliliters.
doi:10.1371/journal.pone.0057347.t001
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time period when mitochondrially-toxic drugs were still widely
used.
Acute pancreatitis has been associated with mutations in CTR
and SPINK-1 genes both in the general population and in HIV-
infected patients [22,23]. Among HIV-infected patients with acute
clinical pancreatitis in a small study, 40% were carriers of CTR or
SPINK-1 mutations [31]. Similarly, a number of gene poly-
morphisms have been described, associated with an increased risk
of developing peripheral neuropathy associated with d4T and ddI
use, including mitochondrial haplotype T [32], the mitochondrial
polymorphism MTND2/HON4917G, specific to haplogroup G
[32], and the 282 C.Y hemochromatosis gene mutation [33].
Among the factors independently associated with the de-
velopment of neuropathy or pancreatitis, we found a low CD4
cell count nadir, a common marker for most toxicities and co-
morbidities [34,35]. Most probably it is a signal of increased
inflammation and/or immune activation, which in turn contribute
to overexpression of nucleoside transporters potentially leading to
increased intracellular d4T-TP levels [36]. The association of TS
and MTHFR polymorphisms with mitochondrial toxicity has
biological plausibility, since genotypes which have a negative
impact on TS activity are associated with higher d4T-TP
intracellular levels and with fat redistribution, a well-known
toxicity of mitochondrial origin [7,8]. Not surprisingly, we found
that low expression TS genotypes are also associated with the
appearance of d4T-induced mitochondrial toxicity in the form of
peripheral neuropathy whereas the association for acute pancre-
atitis showed only a trend to statistical significance, most likely
because of the small number of cases. A potentially contributing
factor could have been that cases had a higher per weight exposure
to d4T than controls, but again this was not an independent
predictor of development of neuropathy or acute pancreatitis.
MTHFR gene is also polymorphic. The best known poly-
morphism consists of a 677 CRT transition in exon 4, which
results in an alanine to valine substitution in the predicted catalytic
domain of MTHFR. This substitution renders the enzyme
thermolabile and homozygotes and heterozygotes have about
70% and 35% reduced enzyme activity, respectively [37]. A
second common polymorphism in the MTHFR gene is a 1298
ARC transition in exon 7 which results in a glutamate to alanine
substitution within a presumed regulatory domain of the protein
[38]. The 1298C allele leads to a decreased enzyme activity, and
individuals who are compound heterozygous for the 677T and
Table 2. Antiretroviral drug exposure in the population
studied.
Parameter Cases (n=43)
Controls
(n =129) P value
ART composition at event 0.0154
PI-based, n (%) 33 (76.7) 69 (53.5)
NNRTI-based, n (%) 10 (23.2) 51 (39.5)
3 NRTIs, n (%) 0 (0.0) 9 (7.0)
NRTI backbone at event
d4T+3TC, n (%) 15 (34.9) 69 (53.5) 0.3335
d4T+ddI, n (%) 23 (53.5) 44 (34.1)
d4T+ABC, n (%) 2 (4.6) 6 (4.6)
d4T alone, n (%) 2 (4.6) 6 (4.6)
d4T+3TC+ABC, n (%) 1 (2.3) 3 (2.3)
d4T+3TC+ddI, n (%) 0 (0.0) 1 (0.8)
Current d4T use, n (%) 0(0) 29 (22.5) 0.0015
Current AZT use, n (%) 13 (30.2) 4 (3.1) ,0.0001
ART duration (m) 110.0 (93.0–138.7) 115.0 (94.7–143.2) 0.4783
Individual drug exposure
AZT exposure, m 43.0 (2.0–70.7) 11.0 (0.0–41.0) 0.0013
AZT exposure, g 559.6 (21.2–998.2) 158.8 (0.0–583.8) 0.0026
d4T exposure, m 26.0 (9.0–47.7) 57.0 (38.7–76.0) ,0.0001
d4T exposure, g 62.9 (21.8–109.8) 135.5 (86.7–177.2) ,0.0001
d4T exposure, mg/kg 1.15 (1.04–1.27) 1.06 (0.92–1.18) 0.0126
3TC/FTC exposure, m 68.0 (38.0–91.7) 70.0 (36.0–103.2) 0.6790
ddI exposure, m 11.0 (3.2–33.0) 17.0 (0.0–60.2) 0.2688
ddC exposure, m 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.7167
ABC exposure, m 2.0 (0.0–46.2) 0.0 (0.0–26.7) 0.0406
TDF exposure, m 0.0 (0.0–45.0) 14.0 (0.0–43.0) 0.3340
EFV exposure, m 0.0 (0.0–0.0) 2.0 (0.0–63.0) 0.0947
NVP exposure. m 6.0 (0.0–46.0) 2.0 (0.0–50.2) 0.6660
ETV exposure, m 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.3068
PI exposure, m 109.0 (28.2–168.7) 46.0 (22.7–97.5) 0.0123
NRTI exposure, m 196.0 (157.2–
247.5)
224.0 (172.0–
267.2)
0.0819
All parameters expressed as median and (interquartile range) unless indicated.
HALS =HIV-1/HAART-associated lipodystrophy syndrome, ART = antiretroviral
therapy, PI = protease inhibitor, NNRTI = non-nucleoside reverse transcriptase
inhibitor, NRTI = nucleoside reverse transcriptase inhibitor, d4T = stavudine,
3TC = lamivudine, FTC = emtricitabine, TDF = tenofovir, ddI = didanosine,
AZT = zidovudine, ddC = zalcitabine, ABC= abacavir, EFV = efavirenz,
NVP = nevirapine, ETV = etravirine, m=months, g = grams, kg = kilograms.
doi:10.1371/journal.pone.0057347.t002
Table 3. Anthropometric, metabolic and fat data in the
population studied.
Cases (n =43) Controls (n =129) P value
Weight, kg 64.7 (60.0–73.7) 65.5 (58.0–73.0) 0.7542
BMI, kg/m2 23.5 (20.5–25.8) 23.8 (21.3–25.7) 0.5769
Waist circumference, cm 89.0 (81.2–93.7) 89.0 (82.7–95.0) 0.8006
WHR 0.96 (0.90–1.02) 0.95 (0.90–1.02) 0.8987
LSGS score, units 4.5 (2.0–10.0) 7.0 (3.4–11.1) 0.0386
Facial score, units 1.0 (0.0–2.0) 2.0 (0.7–2.0) 0.0222
Systolic BP, mm Hg 120 (120–138) 120 (110–130) 0.2025
Diastolic BP, mm Hg 75 (70–80) 75 (70–80) 0.6513
Metabolic syndrome, n
(%)
21 (46.7) 48 (35.5) 0.2498
Total cholesterol, mmol/l 5.07 (4.18–6.03) 5.08 (4.44–5.92) 0.8966
Triglycerides, mmol/l 1.90 (1.17–3.22) 1.63 (1.12–2.54) 0.2752
HDL cholesterol, mmol/l 1.11 (0.95–1.32) 1.23 (0.97–1.53) 0.1690
LDL cholesterol, mmol/l 2.89 (2.28–3.65) 2.89 (2.46–3.50) 0.6693
VLDL cholesterol, mmol/l0.88 (0.54–1.19) 0.77 (0.52–1.11) 0.3723
Fasting glucose, mmol/l 5.30 (5.02–5.87) 5.30 (4.90–6.00) 0.8317
HALS, n (%) 18 (41.9) 75 (58.1) 0.0932
All values expressed as median and (interquartile range) unless specified.
HALS =HIV-1/HAART-associated lipodystrophy syndrome, BMI =body mass
index, WHR=waist-hip ratio, LSGS = lipodystrophy severity grade score, mmol/
l =milimoles per liter, HDL = high density lipoprotein, LDL = low density
lipoprotein, VLDL = very low density lipoprotein, pmol/l = picomoles per liter,
g = grams.
doi:10.1371/journal.pone.0057347.t003
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1298C have a 40–50% reduced MTHFR activity [19]. Therefore,
the non-mutated forms of MTHFR exhibit high enzymatic activity
and should lead to high levels of intracellular 5,10-methylene
tetrahydrofolate that will favor the formation and stability of the
inhibitory ternary complex involving TS, 5,10-methylene tetra-
hydrofolate and deoxyuridine monophosphate [19]. Consequent-
ly, patients with non-mutated alleles should have a decreased TS
activity, which in turn may lead to increased d4T-TP intracellular
levels and to clinical toxicity including pancreatitis and peripheral
neuropathy.
Stavudine-associated side effects may seem of only limited
relevance today, because its use has greatly decreased in developed
countries mainly due to its association with fat distribution
abnormalities [39]. However, its use in developing countries as
part of the starting antiretroviral regimes, with its associated toll of
toxicities [1], is still common despite the WHO recommendation
to substitute for less toxic NRTI when feasible [40].
In summary, our study suggests that d4T-associated acute
pancreatitis and/or peripheral neuropathy are associated with
low-degree TS expression and MTHFR genotype associated with
an increased enzymatic activity. There is a plausible pathogenic
mechanism for such an association since it is well-known that, in
d4T-treated patients, the presence of low-degree TS expression
genotype is associated with increased d4T-TP intracellular
concentrations and MTHFR genotype associated with an in-
creased enzymatic activity contributes to a decreased TS
functionality. This may be of value in tailoring d4T therapy when
needed.
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